Both studies suggest that these T790M-derived neoantigens identified might provide a novel immunotherapeutic approach for overcoming EGFR-TKI resistance in NSCLC patients expressing the T790M mutation and HLA-A*02:01. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.